Compare SWBI & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWBI | SLDB |
|---|---|---|
| Founded | 1852 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.3M | 759.8M |
| IPO Year | 2000 | 2017 |
| Metric | SWBI | SLDB |
|---|---|---|
| Price | $15.21 | $6.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $14.00 | ★ $16.36 |
| AVG Volume (30 Days) | 386.4K | ★ 1.1M |
| Earning Date | 06-17-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $474,661,000.00 | $8,094,000.00 |
| Revenue This Year | $7.61 | N/A |
| Revenue Next Year | $3.72 | N/A |
| P/E Ratio | $309.90 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.73 | $3.01 |
| 52 Week High | $15.79 | $8.87 |
| Indicator | SWBI | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 54.53 | 46.21 |
| Support Level | $13.90 | $6.58 |
| Resistance Level | $15.24 | $6.97 |
| Average True Range (ATR) | 0.42 | 0.47 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 68.48 | 44.56 |
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.